Hospital General Universitario Gregorio Marañón-ko ikertzaileekin lankidetzan egindako argitalpenak (199)

2024

  1. Access to melanoma drugs in Spain: a cross-sectional survey

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

  2. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

    Clinical and Translational Oncology

  3. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

  4. Re-irradiation for progressive Diffuse Intrinsic Pontine Glioma (DIPG): The Spanish experience

    EJC Paediatric Oncology, Vol. 4

  5. SENECA study: staging endometrial cancer based on molecular classification

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 9, pp. 1313-1321

  6. The ELECLA trial: A multicentre randomised control trial on outcomes of neoadjuvant treatment on locally advanced colon cancer

    Colorectal Disease, Vol. 26, Núm. 4, pp. 745-753

2023

  1. Clinical feasibility of combining intraoperative electron radiation therapy with minimally invasive surgery: a potential for electron-FLASH clinical development

    Clinical and Translational Oncology, Vol. 25, Núm. 2, pp. 429-439

  2. Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control

    Journal for immunotherapy of cancer, Vol. 11, Núm. 1

  3. Post-Chemoradiation Metastatic, Persistent and Resistant Nodes in Locally Advanced Rectal Cancer: Metrics and Their Impact on Long-Term Outcome

    Cancers, Vol. 15, Núm. 18

  4. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

    Gynecologic Oncology, Vol. 170, pp. 300-308

  5. SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

    Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 768-775

  6. The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study

    Cancers, Vol. 15, Núm. 11

2022

  1. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial

    The Lancet Oncology, Vol. 23, Núm. 5, pp. 671-681

  2. Intra-Operative Electron Radiation Therapy: An Update of the Evidence Collected in 40 Years to Search for Models for Electron-FLASH Studies

    Cancers, Vol. 14, Núm. 15

  3. Reply to Leonard P. Bokhorst and Berdine L. Heesterman's Words of Wisdom re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial. Eur Urol. 2022;82:441

    European Urology

2021

  1. 10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer

    International journal of radiation oncology, biology, physics, Vol. 111, Núm. 3, pp. S77

  2. Dose volume histogram constraints in patients with head and neck cancer treated with surgery and adjuvant HDR brachytherapy: A proposal of the head and neck and skin GEC ESTRO Working group

    Radiotherapy and Oncology, Vol. 154, pp. 128-134

  3. Evaluation of patient quality care in Spain in prevention of nausea and vomiting induced by chemotherapy

    Journal of Healthcare Quality Research, Vol. 36, Núm. 3, pp. 142-149

  4. In response to Haas RL et al.

    Radiotherapy and Oncology

  5. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5020-5027